Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 06/11/19 → 10/21/23 |
Funding
- Celgene Corporation: $81,274.73
AMGEN: Phase 3 Multicenter Randomized Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Moderate to Severe Genital Psoriasis
- Salvemini, Joann (PI)
- Kaufmann, Tara (CoPI)
- Lozeau, Daniel (CoPI)
- Silverstein, David (PI)
Project: Research